Lauren Santye, Assistant Editor

The combination of emtricitabine/tenofovir alafenamide did not show a treatment benefit over comparator therapies.

Nanoparticle capsule to deliver experimental drug shows promise treating pancreatic cancer.

Top news of the day from across the health care landscape.

Etoposide may cause ovarian tissue damage that impacts the fertility of the unborn child.

Early treatment for HIV and tuberculosis found to improve outcomes.

Organ rejection is caused by donor dendritic cells being rapidly replaced by the recipient’s cells.

Combination therapy may be viable for patients with moderate-to-severe psoriasis unresponsive to non-biologic treatments.

The impact of antiviral hepatitis C drugs in day-to-day life will be examined.

Newly found protein sheds light on insulin resistance and type 2 diabetes.

Researchers advance understanding of how breast cancer drugs work inside human cells.

Findings point to need to target only non-damaged HIV in the body.

Microfluidic device may improve treatment of abnormal blood coagulation.

Patients administered PRO 140 monotherapy reach 2 years of complete remission in trial.

Obesity management in women is vital to reduce the risk of cancer.

Gene therapy may protect against rare neurodegenerative disorder.

Hormone receptor testing may be unnecessary in breast cancer patients.

US National Institutes of Health grant will link universities studying Alzheimer’s disease and related dementia.

Stem cell medical tourism increasingly takes advantage of patients with debilitating conditions.

Marc O'Connor, chief operating officer of Curant Health, discusses how the Affordable Care Act has impacted specialty pharmacy stakeholders.

Pharmacists prefer a distinct name for biosimilars with a nonproprietary name and a designated suffix.

Patients with septic perianal Crohn’s disease have infected abscesses that are difficult to treat.

Study targets how HIV avoids immune system defenses.

Mechanism behind novel BRAF inhibitor resistance among patients with melanoma discovered.

Top news of the day from across the health care landscape.

Angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers carry similar outcomes in study.

Aromatase inhibitors in human estrogen-receptor positive breast cancer can cause tumor mutations.

A 4-dimensional lung scanning platform may advance patient care.

Research identifies which melanoma patients will respond to immunotherapy drugs.

The lack of rigid fatigue descriptions in multiple sclerosis inhibit treatment advances.

Obesity becoming a growing health concern for cancer survivors, specifically breast and colorectal cancers.